Welcome to NewHampshireLifeScience.com

Our network addresses the growing informational and service needs of companies, patients, educators and others in their respective states while providing clients the opportunity to cost effectively advertise their job openings, events, facility availability and other services at the state level, regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting services.

Learn About New Hampshire's BioHistory

Through New Hampshire BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industries in the state of New Hampshire.

Local News...

Free News Release Posting & Archiving Service


• Applera Board of Directors approves proposed separation of its Celera business  Applera Corporation announced that its board of directors has formally approved the proposed separation of the Celera Group from Applera's remaining businesses.
  Celera  May 09, 2008  
  
  
• Progenics Pharmaceuticals reports first quarter 2008 results  Progenics Pharmaceuticals announced its results of operations for the quarter ended March 31, 2008. Revenues for the quarter totaled $14.8 million compared to revenues of $17.6 million for the same period in 2007.
  Progenics Pharmaceuticals, Inc.  May 09, 2008  
  
  
• Keryx Biopharmaceuticals announces first quarter 2008 financial results  Keryx Biopharmaceuticals announced its results for the first quarter ended March 31, 2008. The net loss for the first quarter ended March 31, 2008 was $34,536,000, or $0.79 per share, compared to a net loss of $21,813,000, or $0.50 per share, for the first quarter in 2007.
  Keryx Biopharmaceuticals, Inc.  May 09, 2008  
  
  
• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer  May 08, 2008  
  
  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca  May 08, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Associate Medical Director, Device Safety Allen Thomas Associates, Inc. (NJ)
• Preclinical Study Coordinator I, II, III SNBL USA, Ltd. (WA)
• Quality Assurance Analytical Auditor SNBL USA, Ltd. (WA)
• Senior Scientist/Senior Study Director, General Tox SNBL USA, Ltd. (WA)
• Medical Director Omeros Corporation (WA)

More... | Job Advertising... | About Job Postings...

Upcoming Events...

Free Event Posting Service

• 05/12/2008: World Pharmaceutical Congress
• 05/12/2008: Advertising, Promotion and Labeling Conference
• 05/12/2008: Generic, Supergenerics & Patent Strategies
• 05/12/2008: AIBS Annual Meeting: Climate, Environment, and Infectious Diseases
• 05/13/2008: 2008 Healthcare Investor & Corporate Development Conference

More... | Submit Event | Event Advertising...